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The extracellular matrix (ECM) is a source of bioactive fragments called matricryptins or
matrikines resulting from the proteolytic cleavage of extracellular proteins (e.g., collagens,
elastin, and laminins) and proteoglycans (e.g., perlecan). Matrix metalloproteinases
(MMPs), cathepsins, and bone-morphogenetic protein-1 release fragments, which
regulate physiopathological processes including tumor growth, metastasis, and
angiogenesis, a pre-requisite for tumor growth. A number of matricryptins, and/or
synthetic peptides derived from them, are currently investigated as potential anti-cancer
drugs both in vitro and in animal models. Modifications aiming at improving their efficiency
and their delivery to their target cells are studied. However, their use as drugs is not
straightforward. The biological activities of these fragments are mediated by several
receptor families. Several matricryptins may bind to the same matricellular receptor, and
a single matricryptin may bind to two different receptors belonging or not to the same
family such as integrins and growth factor receptors. Furthermore, some matricryptins
interact with each other, integrins and growth factor receptors crosstalk and a signaling
pathway may be regulated by several matricryptins. This forms an intricate 3D interaction
network at the surface of tumor and endothelial cells, which is tightly associated with
other cell-surface associated molecules such as heparan sulfate, caveolin, and nucleolin.
Deciphering the molecular mechanisms underlying the behavior of this network is
required in order to optimize the development of matricryptins as anti-cancer agents.
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INTRODUCTION
Matricryptins are biologically active fragments released from extracellular matrix (ECM) proteins
and glycosaminoglycans by proteases (Davis et al., 2000). We have extended the definition of
matricryptins to the ectodomains of membrane collagens and membrane proteoglycans, which
are released in the ECM by sheddases, and to fragments of ECM-associated enzymes such as
Abbreviations: ECM, extracellular matrix; EGF, epidermal growth factor; ERK, extracellular signal-regulated kinase; FAK,
focal adhesion kinase; HA, hyaluronan; MAPK, mitogen-associated protein kinase; MMP, matrix metalloproteinase; mTOR,
mammalian target of rapamycin; RHAMM, receptor for hyaluronic acid-mediated motility; TLR, toll-like receptor; VEGF,
vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.
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lysyl oxidase, which initiates the covalent cross-linking of
collagens and elastin, and matrix metalloproteinases (MMPs),
which contribute to ECM remodeling (Ricard-Blum and
Salza, 2014; Ricard-Blum and Vallet, 2015). The molecular
functions of matricryptins and the biological processes they
regulate have been reviewed with a focus on collagen and
proteoglycan matricryptins (Ricard-Blum and Ballut, 2011), on
matricryptins regulating tissue repair (Ricard-Blum and Salza,
2014), angiogenesis (Sund et al., 2010; Boosani and Sudhakar,
2011; Gunda and Sudhakar, 2013), cancer (Monboisse et al.,
2014), and on the proteases releasingmatricryptins (Ricard-Blum
and Vallet, 2015).
Synthetic peptides and/or domains derived frommatricryptin
sequences and recapitulating their biological roles are also able
to regulate angiogenesis and/or cancer in various tumor cells
and cancer models (Rosca et al., 2011). They include sequences
of tumstatin (He et al., 2010; Han et al., 2012; Wang et al.,
2015a), laminins (Kikkawa et al., 2013), endostatin (Morbidelli
et al., 2003), endorepellin (Willis et al., 2013), and the hemopexin
domain of MMP-9 (Ugarte-Berzal et al., 2012, 2014). Neither
these peptides nor the ectodomains of membrane collagens and
syndecans are described here due to space limitation. We focus
on themajor matricryptins, which control cancer, metastasis, and
angiogenesis, a pre-requisite for tumor growth and a therapeutic
target (Folkman, 1971; Welti et al., 2013; Huang et al., 2015), and
on their receptors.
REGULATION OF ANGIOGENESIS, TUMOR
GROWTH AND METASTASIS BY
MATRICRYPTINS
Matricryptins regulate wound healing, fibrosis, inflammation,
angiogenesis, and cancer and are involved in infectious and
neurodegenerative diseases (Ricard-Blum and Ballut, 2011;
Ricard-Blum and Salza, 2014; Ricard-Blum and Vallet, 2015).
Most of the matricryptins regulating angiogenesis and tumor
growth are derived from collagens IV and XVIII (Monboisse
et al., 2014; Walia et al., 2015), elastin (Robinet et al., 2005; Pocza
et al., 2008; Heinz et al., 2010), fibronectin (Ambesi et al., 2005),
laminins (Tran et al., 2008), osteopontin (Bayless and Davis,
2001; Lund et al., 2009; Yamaguchi et al., 2012), MMPs (Bello
et al., 2001; Ezhilarasan et al., 2009), proteoglycans (Goyal et al.,
2011), and hyaluronan (Cyphert et al., 2015; Table 1). They are
released from the ECM by a variety of proteinases (matrixins,
adamalysins, tolloids, cathepsins, thrombin, and plasmin; Ricard-
Blum and Vallet, 2015; Wells et al., 2015).
Matricryptins regulating angiogenesis and tumor growth
target endothelial cells and/or tumor cells (Robinet et al., 2005;
Tran et al., 2008; Sund et al., 2010; Boosani and Sudhakar,
2011; Ricard-Blum and Ballut, 2011; Toupance et al., 2012;
Kikkawa et al., 2013; Monboisse et al., 2014; Ricard-Blum
and Salza, 2014; Monslow et al., 2015; Nikitovic et al., 2015;
Ricard-Blum and Vallet, 2015; Walia et al., 2015). Several
matricryptins inhibit the proliferation and the migration of
endothelial cells, block cell cycle at G1 as shown for anastellin
(Ambesi et al., 2005) and endostatin (Hanai et al., 2002) and
induce apoptosis. Arresten, derived from the C-terminus of the
α1 chain of collagen IV, activates FasL mediated apoptosis for
example (Verma et al., 2013). Endostatin and endorepellin, a
matricryptin of perlecan, induce autophagy of endothelial cells,
the autophagic activity of endorepellin being mediated by a
VEGFR2-dependent pathway (Nguyen et al., 2009; Poluzzi et al.,
2014). A modified endostatin (Endostar) induces autophagy in
hepatoma cells (Wu et al., 2008). Matricryptins normalize tumor
vasculature, which improves the delivery of cytotoxic drugs to
the tumor and hence the response to anti-cancer treatments
(Jain, 2005). Endostatin contributes to the normalization of
tumor vasculature in a lung cancer model (Ning et al., 2012),
and in esophageal squamous cell carcinoma, where it enhances
the effect of radiotherapy and reduces hypoxia (Zhu et al.,
2015), possibly by a crosstalk between cancer and endothelial
cells mediated by the Hypoxia-Inducible Factor and VEGF
expression.
Matricryptins derived from collagens IV and XVIII target
tumoral cells. Arresten inhibits migration and invasion of
squamous cell carcinoma and induces their death (Aikio
et al., 2012). Endostatin inhibits the proliferation of some
cancer cells (e.g., the HT29 human colorectal adenocarcinoma
cell line) but not of others (e.g., the MDA-MB-231 human
mammary adenocarcinoma cell line) (Ricard-Blum et al., 2004).
Matricryptins enhance the sensitivity of tumor cells to a cytotoxic
drug and even reverse in part their resistance to this drug.
A tumstatin peptide increases the sensitivity of non-small cell
lung carcinoma cells to cisplatin (Wang et al., 2015c) and
Endostar enhances the sensitivity to radiation of nasopharyngeal
carcinoma and lung adenocarcinoma xenografts in mice (Wen
et al., 2009).
Matricryptins regulate angiogenesis, tumor growth, and
metastasis by various molecular mechanisms. The anti-
angiogenic activities of tumstatin and endostatin contribute
to tumor suppression by p53 via the upregulation of the α(II)
collagen prolylyl hydroxylase (Folkman, 2006; Teodoro et al.,
2006). Endostatin inhibits proliferation and migration of
glioblastoma cells by inhibiting T-type Ca2+ channels (Zhang
et al., 2012), and its ATPase activity contributes to its anti-
angiogenic and antitumor properties (Wang et al., 2015b). This
matricryptin inhibits hemangioendothelioma by downregulating
chemokine (C-X-C motif) ligand 1 via the inactivation of NF–κB
(Guo et al., 2015).
RECEPTORS AND CO-RECEPTORS OF
MATRICRYPTINS
Matricryptins regulating angiogenesis, tumor growth and
metastasis bind to several receptors, and co-receptors (Figure 1,
Faye et al., 2009a) to modulate signaling pathways and fulfill
their biological functions (Table 1). The other ligands of the
receptors (e.g., ECM proteins, proteoglycans, growth factors, and
chemokines) are not represented in Figure 1 for the sake of
clarity. Pathways regulated by matricryptins in endothelial or
tumor cells via unidentified receptors and/or in other cell types
are mentioned below but are not listed in Table 1.
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TABLE 1 | Matricryptins, receptors, and signaling pathways regulated by matricryptins in endothelial and tumor cells.
Receptors Matricryptins Signaling pathways Cells References
INTEGRINS
α1β1 Arresten (α1 chain of collagen IV) Inhibition of
FAK/c-Raf/MEK1/2/ERK1/2/p38
MAPK pathway; Inhibition of
hypoxia-induced expression of HIF 1α
and VEGF
ECs Sudhakar et al., 2005
HSC-3 human tongue squamous
carcinoma cells
Aikio et al., 2012
α2β1 Endorepellin (C-terminus of perlecan) Activation of SHP-1 ECs Nyström et al., 2009
Activation of the tyrosine phosphatase
SHP-1; Dephosphorylation of
VEGFR2; Down-regulation of VEGFA
ECs Goyal et al., 2011
Down-regulation of VEGFR2 ECs Poluzzi et al., 2014
Procollagen I C-propeptide HT1080 human fibrosarcoma cells Weston et al., 1994
α3β1 Tumstatin (α3 chain of collagen IV) Integrin α3β1 is a trans-dominant
inhibitor of integrin αv
ECs Borza et al., 2006
Canstatin (α2 chain of collagen IV) ECs Petitclerc et al., 2000
α4β1 N-terminal osteopontin fragment HL-60 human promyelocytic leukemia cells Bayless and Davis, 2001
PEX domain of MMP-9 Human chronic lymphocytic leukemia B
cells
Ugarte-Berzal et al., 2012
α4β7 N-terminal osteopontin fragment RPMI 8866 human lymphoblastoid cell line Green et al., 2001
α5β1 Endostatin (α1 chain of collagen XVIII)
KD = 975 and 451 nM, 2 binding
sites, soluble endostatin, immobilized




ECs Sudhakar et al., 2003
Induction of phosphatase-dependent
activation of caveolin-associated Src
family kinases
ECs Wickström et al., 2002
Induction of recruitment of α5β1
integrin into the raft fraction via a
heparan sulfate
proteoglycan-dependent mechanism.
ECs Wickström et al., 2003
Induction of Src-dependent activation
of p190RhoGAP with concomitant
decrease in RhoA activity and
disassembly of actin stress fibers and
focal adhesions
Hemangioendothelioma-derived cells Guo et al., 2015
N-terminal osteopontin fragment Human colorectal adenocarcinoma
(SW480 cells)
Yokosaki et al., 2005
α6β1 Tumstatin (α3 chain of collagen IV) ECs Maeshima et al., 2000
α9β1 N-terminal osteopontin fragment Human colorectal adenocarcinoma
(SW480 cells)
Yokosaki et al., 2005
αvβ3 Endostatin (α1 chain of collagen XVIII)
KD = 1.2µM and 501 nM, 2 binding
sites, soluble endostatin, immobilized
full-length integrin; (Faye et al., 2009b)
ECs Rehn et al., 2001
(Continued)
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TABLE 1 | Continued
Receptors Matricryptins Signaling pathways Cells References
Canstatin (α2 chain of collagen IV) Induction of two apoptotic pathways
through the activation of caspase-8
and caspase-9
ECs Magnon et al., 2005
Induction of caspase 9-dependent
apoptotic pathway
Human breast adenocarcinoma cells
(MDA-MB-231)
Magnon et al., 2005
ECs Petitclerc et al., 2000
Tumstatin (α3 chain of collagen IV) Inhibition of Cap-dependent translation
(protein synthesis) mediated by
FAK/PI3K/Akt/mTOR/4E-BP1 pathway
ECs Maeshima et al., 2000;
Sudhakar et al., 2003
ECs Petitclerc et al., 2000
Inhibition of the activation of FAK,
PI3K, protein kinase B (PKB/Akt), and
mTOR
ECs Maeshima et al., 2002
It prevents the dissociation of
eukaryotic initiation factor 4E protein
from 4E-binding protein 1
Stimulation of FAK and PI3K
phosphorylation
Human metastatic melanoma cell line
(HT-144)
Pasco et al., 2000
Inhibition of the growth of tumors
dependent on Akt/mTOR activation
(functional PTEN required)
Human glioma cells Kawaguchi et al., 2006
Tetrastatin (α4 chain of collagen IV)
KD = 148 nM (2-state model, soluble
tetrastatin, immobilized full-length
integrin)
Human melanoma cells (UACC-903) Brassart-Pasco et al.,
2012
NC1 domain of α6 chain of collagen
IV
ECs Petitclerc et al., 2000
Procollagen II N-propeptide Human chondrosarcoma cell line (hCh-1) Wang et al., 2010
PEX domain of MMP-2 ECs Brooks et al., 1998
N-terminal osteopontin fragment Human colorectal adenocarcinoma
(SW480 cells)
Yokosaki et al., 2005
VGAPG, VGAP (elastin peptides) Human melanoma cell lines (WM35 and
HT168-M1)
Pocza et al., 2008
αvβ5 Endostatin (α1 chain of collagen XVIII) ECs Rehn et al., 2001
Canstatin (α2 chain of collagen IV) Induction of two apoptotic pathways
through the activation of caspase-8
and caspase-9
ECs Magnon et al., 2005
Induction of caspase 9-dependent
apoptotic pathway
Human breast adenocarcinoma cells
(MDA-MB-231)
Magnon et al., 2005
ECs Petitclerc et al., 2000
Tumstatin (α3 chain of collagen IV) ECs Pedchenko et al., 2004
Procollagen II N-propeptide Human chondrosarcoma cell line (hCh-1) Wang et al., 2010
N-terminal osteopontin fragment Human colorectal adenocarcinoma
(SW480 cells)
Yokosaki et al., 2005
αvβ6 N-terminal osteopontin fragment Human colorectal adenocarcinoma
(SW480 cells)
Yokosaki et al., 2005
(Continued)
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TABLE 1 | Continued
Receptors Matricryptins Signaling pathways Cells References
GROWTH FACTOR RECEPTORS
VEGFR1 Endostatin (α1 chain of collagen XVIII) ECs Kim et al., 2002
Endorepellin (C-terminus of perlecan)
KD = 1 nM (soluble endorepellin,
immobilized ectodomain of VEGFR1)
ECs Goyal et al., 2011
VEGFR2 Endostatin (α1 chain of collagen XVIII) Inhibition of VEGF-induced tyrosine
phosphorylation of VEGFR2 and
activation of ERK, p38 MAPK, and
p125FAK
ECs Kim et al., 2002
Endorepellin (C-terminus of perlecan) Attenuation of VEGFA-evoked
activation of VEGFR2 at Tyr1175
ECs Goyal et al., 2011
KD = 0.9 nM (soluble endorepellin,
immobilized ectodomain of VEGFR2)
Attenuation of both the
PI3K/PDK1/Akt/mTOR and the
PKC/JNK/AP1 pathways
ECs Goyal et al., 2012
Induction of the formation of the
Peg3-Vps34-Beclin 1 autophagic
complexes via inhibition of the
PI3K/Akt/mTOR pathway
ECs Poluzzi et al., 2014
Induction of autophagy through a
VEGFR2 dependent but α2β1
integrin-independent pathway
EGFR Laminin-332 EGF-like (domain III) of
the γ2 chain
Stimulation of EGFR phosphorylation;
Induction of ERK phosphorylation
Human breast adenocarcinoma cells
(MDA-MB-231)




Activation of Rac1, increase in
phosphorylation of ERK, PAK and
VE-cadherin




Endostatin (α1 chain of collagen XVIII) ECs Karumanchi et al., 2001
Glypican-
4
Endostatin (α1 chain of collagen XVIII) ECs Karumanchi et al., 2001
Syndecan-
1
LG45 domain of the α3 chain of
laminin-332
HT1080 human fibrosarcoma cells Carulli et al., 2012
Syndecan-
4
LG45 domain of the α3 chain of
laminin-332





Elastin peptides (xGxxPG sequences) 67 kDa elastin binding protein (an
alternatively spliced form of
β-galactosidase)
ECs Robinet et al., 2005
Human melanoma cell lines (WM35 and
HT168-M1)




VGVAPG and VAPG (elastin peptides) Human melanoma cell lines (WM35 and
HT168-M1)
Pocza et al., 2008
(Continued)
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TABLE 1 | Continued





VGVAPG (elastin peptide) M27 subline of murine Lewis lung
carcinoma
Blood and Zetter, 1993
AGVPGLGVG and AGVPGFGAG
(elastin peptides)
Human lung carcinoma cells Toupance et al., 2012
CD44, RHAMM AND TLR4
CD44 Hyaluronan oligosaccharides (3–10
disaccharides)
PKC-α phosphorylation of γ-adducin,
a membrane cytoskeletal and
actin-binding protein, Activation of
ERK1/2
ECs Matou-Nasri et al., 2009
Stimulation of ERK1/2 signaling
Inhibition of CD44 clustering (3–10
disaccharides)
Human breast cancer cells (BT-159, ductal
carcinoma)
Yang et al., 2012
N-terminal osteopontin fragment
(Leu1-Gly127)
CD44-mediated OPN binding requires
β1 integrin
Rat BDX2 fibrosarcoma cells Katagiri et al., 1999
C-terminal osteopontin fragment
(Leu132-Asn278)
CD44-mediated OPN binding requires
β1 integrin
Rat BDX2 fibrosarcoma cells Katagiri et al., 1999
Osteopontin fragment (5 kDa,
residues 167–210)
Human hepatocellular carcinoma cells Takafuji et al., 2007
PEX domain of MMP-9 Human chronic lymphocytic leukemia cells Ugarte-Berzal et al., 2014
LYVE-1 Hyaluronan oligosaccharides (3–10
disaccharides)
Increased tyrosine phosphorylation of
protein kinase Cα/βII and ERK1/2
ECs Wu et al., 2014
TLR4 Hyaluronan oligosaccharides (4, 6,
8-mer HA fragments)
ECs Taylor et al., 2004
RHAMM Hyaluronan oligosaccharides (2–10
disaccharides)





Matou-Nasri et al., 2009
CELL SURFACE ASSOCIATED PROTEIN
Nucleolin Endostatin (α1 chain of collagen XVIII)
KD = 13 nM; (Shi et al., 2007)
Hemangioendothelioma-derived cells Guo et al., 2015
Receptors identified in other cell types and the associated signaling pathways are mentioned in the text. 4E-BP1, eukaryotic translation initiation factor 4E-binding protein 1; AP1,
activation protein 1; Cdk1/Cdc2, cyclin-dependent kinase-1; CXCR2, CXC chemokine receptor 2; CXCL1, Chemokine (C-X-C motif) ligand 1; EC, endothelial cell; EGFR, epidermal
growth factor receptor; ERK, extracellular signal-regulated kinase; FAK, focal adhesion kinase; HIF, hypoxia-inducible factor; JNK, c-Jun N-terminal kinases; LG, laminin G domain-like;
LYVE-1, Lymphatic vessel endothelial hyaluronan receptor 1; MAPK, mitogen-activated protein kinase; MEK, mitogen-activated protein kinase kinase; MMP, matrix metalloproteinase;
PAK, p21-activated kinase; PDK, phosphoinositide-dependent kinase; PI3K, phosphatidylinositol 3-kinase; PKB, protein kinase B; PKC, protein kinase C; PTEN, phosphatase and tensin
homolog; RHAMM, receptor for HA-mediated motility; SHP-1, Src homology-2 protein phosphatase-1; TLR4, Toll-like receptor 4; VE-cadherin, vascular endothelial cadherin; VEGFA,
vascular endothelial growth factor A; VEGFR, Vascular endothelial growth factor receptor.
Integrins
There are 24 integrins comprised of an α subunit and a β subunit
(Barczyk et al., 2010). They lack intrinsic kinase activity and
are the major adhesion receptors of the ECM, controlling ECM
assembly, cell-matrix interactions, cell migration, and tumor
growth (Missan and DiPersio, 2012; Xiong et al., 2013). A
number of matricryptins bind to integrins at the surface of tumor
and/or endothelial cells (Table 1). Matricryptins also interact
with purified integrins (e.g., αvβ5 integrin for endostatin; Rehn
et al., 2001; Faye et al., 2009b), or on other cell types. The
αvβ3 integrin is the main receptor targeted by matricryptins
(Figure 1).
Anastellin decreases the activation state of α5β1 integrin
on endothelial cells (Ambesi and McKeown-Longo, 2014).
Arresten interacts with α3β1/αvβ3 and α1β1/α2β1 integrins at
the surface of HPV-16-immortalized proximal tubular epithelial
cells and mesangial cells respectively, whereas tumstatin binds
to immortalized glomerular epithelial cells through α3β1 and
α2β1 integrins (Aggeli et al., 2009). The above integrins
are also involved in the effects of matricryptins on other
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FIGURE 1 | Interaction network of matricryptins (right) and their receptors (left) expressed at the surface of endothelial and cancer cells. ab, alpha and
beta integrin subunits; C-Pro Col, C-propeptide of procollagen; CXCR, chemokine CXC receptor; ECM, extracellular matrix; EGF, epidermal growth factor; EGFR,
epidermal growth factor receptor; EP, elastin peptide; ER, endorepellin; ERC, elastin receptor complex; ELR, elastin receptor; ES, endostatin; G3R, galectin-3
receptor; GFR, growth factor receptor; HA oligo, hyaluronan oligosaccharide; HAR, hyaluronan receptor; LN LG45, laminin domain LG45; LIR, lactose insensitive
receptor; LYVE-1, lymphatic vessel endothelial hyaluronan receptor 1; N-Pro Col, N-propeptide of procollagen; MMP, matrix metalloproteinase; NC1, non-collagenous
domain; OPN, osteopontin; PEX, hemopexin domain; PG, proteoglycan; RHAMM, receptor for hyaluronic acid-mediated motility; TLR4, toll-like receptor; VEGFR,
vascular endothelial growth factor receptor.
cell types. Endostatin, generated by cerebellar Purkinje cells,
contributes to the organization of climbing fiber terminals in
these neurons by binding and signaling through α3β1 integrin
(Su et al., 2012). The adhesion of smooth muscle cells to
anastellin is mediated by both β1 integrins and cell surface
heparan sulfate proteoglycans, which triggers ERK1/2 activation
in these cells (Mercurius and Morla, 2001) and the induction
of osteoclast apoptosis by the N-propeptide of procollagen II
is mediated by αv or β3 integrin subunits (Hayashi et al.,
2011).
Growth Factor and Chemokine Receptors
Growth factor receptors belong to the tyrosine kinase receptor
family. They regulate cell proliferation, differentiation, cell cycle,
survival and apoptosis and play a role in cancer (McDonell et al.,
2015). VEGR receptors 1–3 (Roskoski, 2008; Grünewald et al.,
2010; Simons, 2012) and EGF receptor (Lemmon et al., 2014)
interact with matricryptins (Table 1). Two endostatin peptides
bind to VEGFR3 (Han et al., 2012, 2015) and EGF-like repeats
of tenascin C interact with EGFR, inducing phosphorylation of
the receptor and of ERK MAP kinases in NR6 mouse fibroblasts
(Swindle et al., 2001). Endorepellin simultaneously engages
VEGFR2 and α2β1 integrin, both expressed by endothelial
cells, and regulate angiogenesis and autophagy through a dual
receptor antagonism (Goyal et al., 2011; Poluzzi et al., 2014).
Anastellin inhibits lysophospholipid (Ambesi and McKeown-
Longo, 2009) and VEGF165-dependent signaling in endothelial
cells by preventing the formation of the complex containing
VEGFR2 and neuropilin-1 at the surface of endothelial cells
(Ambesi and McKeown-Longo, 2014). One matricryptin of
collagen I interacts with a member of the chemokine receptor
family, the CXC chemokine receptor 2 (Stadtmann and Zarbock,
2012; Veenstra and Ransohoff, 2012).
Cell Surface Proteoglycans
Proteoglycans are divided into intracellular, pericellular,
extracellular, and cell-surface families (Iozzo and Schaefer, 2015).
Syndecans are transmembrane heparan sulfate proteoglycans
(Couchman et al., 2015), which play a role in cell adhesion,
migration, receptor trafficking, growth factor interactions,
angiogenesis (De Rossi and Whiteford, 2014) and cancer
(Barbouri et al., 2014). They are enzymatically shed from the
cell surface and compete with their membrane forms for ligand
binding (Manon-Jensen et al., 2010). They act in synergy with
integrins to control cell adhesion and other biological processes
(Morgan et al., 2007; Roper et al., 2012; Humphries et al.,
2015), and the binding of heparan sulfate chains to integrin
α5β1 promotes cell adhesion and spreading (Faye et al., 2009b).
Syndecans act as co-receptors of VEGF and control tumor
progression in association with integrins (Grünewald et al.,
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2010; Soares et al., 2015). Glypicans, membrane-associated
proteoglycans with a glycosylphosphatidyl anchor, regulate Wnt,
Hedgehog, fibroblast growth factor, and bone morphogenetic
protein signaling (Filmus et al., 2008; Iozzo and Schaefer, 2015).
One matricryptin, endostatin, binds to glypicans via their
heparan sulfate chains (Karumanchi et al., 2001).
Elastin Receptors
The Elastin Receptor Complex (ERC) is composed of two
membrane associated proteins (the protective protein/cathepsin
A and neuraminidase-1) and of the elastin-binding protein,
an inactive spliced variant of lysosomal β-galactosidase
(Blanchevoye et al., 2013). Elastin peptides activate extracellular
signal-regulated kinase 1/2 via a Ras-independent mechanism
in fibroblasts (Duca et al., 2005), the enzymatic activity of
neuraminidase-1 being responsible for signal transduction
(Duca et al., 2007). Another, still unidentified, receptor of elastin
peptides exists at the surface of macrophages (Maeda et al., 2007).
Furthermore, elastin peptides regulate tumor cell migration and
invasion through an Hsp90-dependent mechanism (Donet et al.,
2014).
CD44, Receptor for HA-Mediated Motility
(RHAMM) and Toll-Like Receptors (TLRs)
Hyaluronan, a non-sulfated glycosaminoglycan, has two major
receptors, CD44 and RHAMM, which mediate its roles in
inflammation and cancer (Toole, 2009; Misra et al., 2015;
Nikitovic et al., 2015). The binding to, and activation of, receptors
depend on the size of HA, its oligosaccharides stimulating
angiogenesis (Gao et al., 2008). CD44, which has several isoforms
regulates cell proliferation, adhesion and migration, and is
involved in tumorigenesis (Jordan et al., 2015). A sequence
in the hemopexin domain of MMP-9 (PEX9) impairs tumor
cell adhesion to PEX9/MMP9 through interaction with CD44
(Ugarte-Berzal et al., 2014). RHAMM has splicing variants and is
located inside the cell and on the cell surface, where it is anchored
via a glycosylphosphatidylinositol (Tolg et al., 2014; Misra
et al., 2015). Toll-like receptors are pattern recognition receptors
involved in innate immunity (Rakoff-Nahoum and Medzhitov,
2009). Low-molecular weight hyaluronan induces the formation
of a complex containing CD44, TLR2/TLR4, the actin filament-
associated protein AFAP-110, and a myeloid differentiation
factor MyD88, which triggers cytoskeleton activation and results
in tumor invasion (Bourguignon et al., 2011).
Other Membrane and Cell
Surface-Associated Proteins
Matricryptins form complexes with membrane or membrane-
associated proteins. Caveolin- participates in the formation of
membrane caveolae, which are platforms for signal transduction
(Fridolfsson et al., 2014) and forms a complex with α5β1 integrin
and endostatin in lipid rafts at the endothelial cell surface
(Wickström et al., 2002) (Table 1). Nucleolin, a multifunctional
protein, localized inside the cell and at the cell surface (Berger
et al., 2015), binds to endostatin and triggers its internalization in
endothelial cells in association with the urokinase plasminogen
activator receptor and the α5β1integrin (Shi et al., 2007; Song
et al., 2012).
MATRICRYPTINS AS POTENTIAL DRUGS
Matricryptins are potential anti-cancer drugs, either alone,
or in combination with other treatments, but their use in
pre-clinical and clinical studies remains challenging. Indeed
matricryptins may display opposite activities depending on
the context. The anti-tumoral effect of endostatin is enhanced
by silencing of the proteoglycan versican, which decreases
the inflammatory and immunosuppressive changes triggered
by anti-angiogenic therapy (Wang et al., 2015d). However,
endostatin may induce the proliferation of carcinoma cells,
whereas its effect on cancer invasion is modulated by the
tumor microenvironment (Alahuhta et al., 2015). Endorepellin
stimulates angiogenesis in a stroke model by increasing VEGF
levels, and exerts a neuroprotective effect in this model via
α5β1 integrin and VEGFR2 (Lee et al., 2011). In addition,
endostatin exhibits a biphasic response curve both for its anti-
angiogenic and anti-tumoral properties (Celik et al., 2005;
Javaherian et al., 2011), which requires to test a large range
of concentrations to determine the optimal dose for treatment.
Another challenge is that matricryptins may themselves contain
cryptic sequences displaying opposite activities as reported for
the anti-angiogenic matricryptin endostatin, which contains an
embedded pro-angiogenic sequence (Morbidelli et al., 2003).
Different matricryptins regulate the same biological process
in an opposite way as reported for the regulation of the
angiogenic signaling in choroidal endothelial cells by hexastatin
and elastokines (Gunda and Sudhakar, 2013), or distinct steps
of a biological process as described for anastellin and endostatin
(Neskey et al., 2008).
Matricryptins can be modified to extend the half-life, and
their efficacy (Xu et al., 2007; Zheng, 2009; Ricard-Blum and
Ballut, 2011; Ricard-Blum and Salza, 2014). Most of the examples
detailed below concern endostatin, which is extensively studied
and has been approved for the treatment of non-small-cell lung
cancer in China (Biaoxue et al., 2012) under a recombinant
form, Endostar, which contains an extra metal chelating sequence
(MGGSHHHHH) at the N-terminus enhancing its solubility and
stability (Jiang et al., 2009). PEGylation (Nie et al., 2006; Tong
et al., 2010; Tan et al., 2012; Guo et al., 2014), and the fusion of
endostatin to low molecular weight heparin or to the Fc region
of an IgG enhance its half-life and its anti-angiogenic, or anti-
tumoral activities (Lee et al., 2008; Jing et al., 2011; Ning et al.,
2012; Tan et al., 2012; Li et al., 2015b).
Tumors may escape from anti-tumoral and anti-angiogenic
matricryptins by upregulating factors, which stimulate
angiogenesis (Fernando et al., 2008). The combination of
matricryptins with inhibitors of pro-angiogenic pathways,
chemotherapy, or radiotherapy enhance their therapeutic
efficacy. Tumstatin has been fused to another endogenous
inhibitor of angiogenesis, vasostatin (Gu et al., 2014) and to
tumor necrosis factor α, which has anti-tumoral and anti-
angiogenic properties, which results in a more effective fusion
protein than tumstatin alone (Luo et al., 2006). Endostatin has
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been fused to the proapoptotic domain (BH3) of the BAX protein
(Chura-Chambi et al., 2014), to tumor necrosis factor-related
apoptosis-inducing ligand (Zheng et al., 2013) and one of its
anti-angiogenic sequences to an heptapeptide inhibitor of MMPs
(Qiu et al., 2013). Endostatin has also been fused to protein
sequences targeting it to tumors and/or tumor vasculature
such as humanized antibodies against tyrosine kinase-type
receptor HER2 (Shin et al., 2011) or against tumor-associated
glycoprotein 72 highly expressed in human tumor tissues (Lee
et al., 2015), the RGD integrin-binding sequence (Jing et al.,
2011), and a liver-targeting peptide (circumsporozoite protein
CSP I-plus (Ma et al., 2014; Bao et al., 2015).
Several approaches improve the delivery of matricryptins
to tumors and endothelial cells (Xu et al., 2007; Ricard-
Blum and Ballut, 2011) such as conditionally replicating
oncolytic adenoviral vector for arresten (Li et al., 2015a), naked
plasmid electrotransfer in muscle for tumstatin overexpression
(Thevenard et al., 2013), and the nonpathogenic and anaerobic
bacterium, Bifidobacterium longum, which proliferates in the
hypoxic zones within tumors for tumstatin expression (Wei
et al., 2015). Endostatin has been delivered in polylactic acid
nanoparticles (Hu and Zhang, 2010), in gold nanoshells, which
are very efficient on lung cancer cells when associated with near-
infrared thermal therapy (Luo et al., 2015) and into microbubbles
in combination with ultrasonic radiation in a cancer model
(Zhang et al., 2014). Dendrimers mimicking the surface structure
of endostatin and loaded with anticancer drug, result in both
angiogenesis inhibition by endostatin and death of cancer cells
by the anticancer drug (Jain and Jain, 2014).
Clinical trials of endostatin mostly focus on solid tumors
in association with cytotoxic drugs (https://clinicaltrials.gov/).
These trials include phase I (Lin et al., 2007; Chen et al.,
2014), II (Lu et al., 2015), and III trials (Wang et al.,
2005). Although endostatin did not improve overall survival,
progression-free survival, and objective response rate when
combined with etoposide and carboplatin in patients with
extensive-stage small-cell lung cancer phase II trial (Lu et al.,
2015), it significantly improves the response rate and median
time to tumor progression when combined with vinorelbine
and cisplatin in advanced non-small cell lung cancer patients
compared to chemotherapy alone (Wang et al., 2005). Promising
results have been obtained with endostatin associated with
paclitaxel and 5-fluorouracile in patients with refractory
malignant ascites secondary to ovarian cancer (Zhao et al., 2014).
CONCLUDING REMARKS
Several matricryptins such as the propeptide of lysyl oxidase,
which is a tumor suppressor (Min et al., 2007; Ozdener
et al., 2015) and the netrin-like domain of procollagen C-
proteinase enhancer-1, a new anti-angiogenic matricryptin (Salza
et al., 2014), warrant further investigation in angiogenesis, and
tumor models to decipher their mechanisms of action at the
molecular and cellular levels. Matricryptins are useful for treating
fibroproliferative disorders (Yamaguchi et al., 2012; Wan et al.,
2013) and fundus oculi angiogenesis diseases (Zhang et al.,
2015). The finding that a peptide derived from endostatin
can be delivered orally in vivo and exerts anti-fibrotic activity
(Nishimoto et al., 2015) paves the way for the development of new
matricryptin drugs with oral bioavailability, which is a preferred
administration route for long-term treatment. Matricryptins are
also used as biomarkers in serum and in cerebrospinal fluid
(Ricard-Blum and Vallet, 2015; Salza et al., 2015) and may serve
as imaging agents when labeled with (99m)Tc as shown for
endostatin (Leung, 2004) and tumstatin (He et al., 2015) and
for tumstatin conjugated to iron oxide nanoparticles (Ho et al.,
2012).
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